Screener
Relay Therapeutics, Inc. RLAY Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -2,999.4%+1,106pp | -2,776.6%+2,002pp | -1,971.5%+1,751pp | -3,914.4%-120pp | -4,105.6%-3,092pp | |
| Net margin | -2,763.6%+965pp | -2,554.1%+1,787pp | -1,800.5%+1,574pp | -3,561.4%-112pp | -3,728.4%-2,812pp | |
| Returns | ||||||
| Return on equity | -36.8%+9.5pp | -40%+5.4pp | -41.1%+3.0pp | -41.1%+1.5pp | -46.2%-3.0pp | |
| Return on invested capital | -44.8%+13.1pp | -51.8%+3.8pp | -49.7%+4.9pp | -50.9%+2.7pp | -57.9%-3.8pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 18.3×-2.7× | 22.1×+2.2× | 22.6×+6.7× | 19.1×+0.7× | 20.9×+5.3× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Valuation | ||||||
| Market capitalization | $4.3B+611% | $1.78B+300% | $1.47B+113% | $899.99M-4.3% | $567.48M-33.5% | |
| Price / sales | 415.9×+343× | 166.6×+109× | 95.5×+26.6× | 107.7×+13.7× | 67.9×+43.7× | |
| Price / book | 4.8×+3.9× | 2.8×+2.2× | 2.6×+1.7× | 1.5×+0.4× | 0.9×-0.4× |
FAQ
- Where do Relay Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Relay Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
